Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

CTI Will File sNDA For Zevalin In Follicular Lymphoma, CEO Bianco Tells DAILY

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Improvement in progression-free survival is seen in patients with advanced follicular lymphoma following treatment with Zevalin.

You may also be interested in...



Bayer Schering Gets Positive European Review For Zevalin In Follicular Lymphoma

CTI anticipates second-half filing in the U.S., CEO Bianco tells “The Pink Sheet” DAILY.

Bayer Schering Gets Positive European Review For Zevalin In Follicular Lymphoma

CTI anticipates second-half filing in the U.S., CEO Bianco tells “The Pink Sheet” DAILY.

Cell Therapeutics Cuts Expenses As It Transforms Into Commercial Operation

CTI will reduce development staff as it shores up its commercial team ahead of Zevalin launch.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

See All
UsernamePublicRestriction

Register

PS065342

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By